TRDA
Entrada TherapeuticsFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-21
+
Peers tracked
11
U.S. public peers
Grade Position
Below peers
vs peer average
TRDA vs peer average
30/100
TRDA vs. peer average (F vs. D)
Grade spread
A 2 · B 1 · D 3 · F 5
Graded peers loaded
Coverage
11 graded
100% of tracked
Peer overview
ENTA is the first available peer comparator.
Clinical-stage therapeutics peer where valuation is also dominated by readout timing and pipeline conversion risk; useful as a small-cap R&D execution comp, though not a direct Duchenne exon-skipping match.
✓Peer source comes from the stored AI memo or peer model
✓Grades and factor rows use RankAlpha API data when available
✓Missing peer scores remain blank instead of being estimated
✓Side-by-side comparison keeps the data contract visible
TRDA
Entrada Therapeutics
ENTA
Enanta
Grade
F
D
Momentum
7
60
Value
41
41
Sentiment
61
-
Setup Bias
Net —
-
Market Cap
-
-
Posture
Defensive
Defensive
Grade position vs ENTA
TRDA / ENTA
Grade Position
Below peers
TRDA vs. peer average (F vs. D)
30/100
Momentum
7
ENTAValue
41
TRDASentiment
61
-Rotation landscape
Peers ranked by the order returned from the peer source, with grades from the API.
Rank
Ticker
Company
Grade
Grade score
vs TRDA
ENTA is the first peer returned for this comparison set.